Celltrion said Tuesday that it attained sales of 1.84 trillion won ($1.65 billion) and an operating profit of 712.1 billion won last year, recording a business profit rate of 38.5 percent.

Celltrion’s 2020 sales and operating profits registered growth rates of 63.9 percent and 8.4 percent from 2019, breaking records for two years in a row.

The comprehensive healthcare provider attributed its excellent performance of last year to the expanded biosimilar product line and resultant supply increase as well as improved production efficiency at additional facilities at its first plant.

“The flagship product line maintained a solid market share in Europe,” the company said in a public notice.

In the third quarter of last year, Remsima accounted for 52.8 percent of the European market, followed by Truxima’s 38 percent and Herzuma’s 15.9 percent. In the U.S., Inflectra, Remsima U.S. brand name, accounted for 11.8 percent of market share, and Truxima took up 19.8 percent.

This year, Celltrion plans to expand its biosimilars lineup further, win global licenses for Regkirona, its Covid-19 antibody treatment, accelerate market penetration for Remsima, and increase production through establishing its third plant.

The company has already received approval from the European Commission (EC) to sell Yuflyma, its high-concentration Humira biosimilar.

Celltrion is also conducting clinical trials for various other biosimilars, such as CT-P16 (Avastin biosimilar), CT-P39 (Xolair biosimilar), CT-P41 (Prolia biosimilar), CT-P42 (Eylea biosimilar), and CT-P43 (Stelara biosimilar).

The company obtained conditional approval for Regkirona from the Ministry of Food and Drug Safety in February and planned to get nods from the U.S. and European regulators in the first half of the year by applying for conditional approval and emergency use approval.

At home, it has completed the production of Regkirona to treat 100,000 patients and plans to increase its output to meet an additional demand of up to 3 million patients annually.

To cope with the Covid-19 variants in the future, the company has established a variant response platform and began developing a cocktail treatment that combines Regkirona with an antibody candidate, which showed neutralizing ability toward the U.K. and South African variants.

Remsima SC, one of Celltrion's next-generation growth engines, acquired sales approval in Canada in February, speeding up its entry into the North American market.

To cope with the rising demand for its biosimilars and secure stable production, Celltrion has been building a third plant and research center in Songdo, Incheon, since November of last year.

“Despite the Covid-19 pandemic last year, our major product lines grew, allowing the company to demonstrate the best performance ever,” a company official said. “We will try to keep developing into a global biotechnology and healthcare company.”